CD30-directed CAR-Ts co-expressing CCR4 in R/R HL and CD30+ CTCL

CD30, a promising target for CAR-T therapy in Hodgkin lymphomaПодробнее

The evolving treatment landscape of R/R LBCLПодробнее

Dual-targeting CD30/PDL1 CAR-T therapy in Hodgkin lymphomaПодробнее

‘Off-the-shelf’ EBV-specific CAR-T cells for Hodgkin lymphomaПодробнее

The Potential of CD30 CAR T Cell Therapy for the Treatment of CD30-Positive LymphomasПодробнее

Carlos Ramos | ASH 2018 | CD30 CAR-T therapy for HLПодробнее

Infusion of CD30 CAR T-cells following AuHCT in patients with lymphomaПодробнее

Peripheral T-Cell Lymphoma: What is New on the Horizon?Подробнее

New agents and therapeutic options for T-cell lymphomaПодробнее

CD30+ cutaneous T-cell lymphoma (Medical Condition)Подробнее

Allo-CART and NK therapies in the pipeline for the treatment of hematological malignanciesПодробнее

ECHELON-2 trial updates and the role of transplant in CD30-positive PTCLПодробнее

Mycosis Fungoides (Non-Hodgkin's Lymphoma) - Cancer Treatment I Max Hospital, Shalimar BaghПодробнее

Advances in CAR-T therapy for lymphomaПодробнее

Jeff's rare realityПодробнее

What is Cutaneous T Cell Lymphoma?Подробнее

Advances in AL amyloidosisПодробнее

Mycosis fungoides linked to second cancer riskПодробнее